1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

Targeting the Human Genome–Microbiome Axis for Drug Discovery: Inspirations from Global Systems Bi

Targeting the Human Genome–Microbiome Axis for Drug Discovery: Inspirations from Global Systems Bi

  1. catseye
    Liping Zhao, Jeremy K. Nicholson, Aiping Lu, Zhengtao Wang, Huiru Tang, Elaine Holmes, Jian Shen, Xu Zhang, Jia V. Li, John C. Lindon

    Journal of Proteome Research, 2012; 11 (7)

    ABSTRACT:
    Most chronic diseases impairing current human public health involve not only the human genome but also gene−environment interactions, and in the latter case the gut microbiome is an important factor. This makes the classical single drug−receptor target drug discovery paradigm much less applicable. There is widespread and increasing international interest in understanding the properties of traditional Chinese medicines (TCMs) for their potential utilization as a source of new drugs for Western markets as emerging evidence indicates that most TCM drugs are actually targeting both the host and its symbiotic microbes.
    In this review, we explore the challenges of and opportunities for harmonizing Eastern− Western drug discovery paradigms by focusing on emergent functions at the whole body level of humans as superorganisms. This could lead to new drug candidate compounds for chronic diseases targeting receptors outside the currently accepted “druggable genome” and shed light on current high interest issues in Western medicine such as drug−drug and drug−diet−gut microbial interactions that will be crucial in the development and delivery of future therapeutic regimes optimized for the individual patient.